HUTCHMED Begins Phase III for HMPL-760 HUTCHMED initiated a Phase III trial for HMPL-760 in China on Mar 23, 2026, advancing its lymphoma program to a pivotal stage and shifting valuation drivers to execution and differentiation.

HUTCHMED Begins Phase III for HMPL-760: HUTCHMED initiated a Phase III trial for HMPL-760 in China on Mar 23, 2026, advancing its lymphoma program to a pivotal stage and shifting valuation drivers to execution and… 👈 Read full analysis #HUTCHMED #PhaseIII #HMPL760 #LymphomaTreatment #Oncology

Hutchmed scores with drug for rare autoimmune disease Hutchmed is preparing to file for approval of its drug for the rare disorder wAIHA in China, after chalking up a win in a pivotal phase 2/3 trial

#Hutchmed is preparing to file for approval of a drug for the rare #autoimmune disorder warm antibody autoimmune haemolytic #anaemia (#wAIHA) in #China, after chalking up a win in a pivotal phase 2/3 trial.

pharmaphorum.com/news/hutchme...

Innovent and HUTCHMED Achieve Milestone in Kidney Cancer Treatment with Promising Study Results Innovent Biologics and HUTCHMED's latest study shows promising results for treating advanced renal cell carcinoma, meeting crucial clinical endpoints.

Innovent and HUTCHMED Achieve Milestone in Kidney Cancer Treatment with Promising Study Results #China #Suzhou #Innovent #Sintilimab #HUTCHMED